Zurich Cantonal Bank’s Soleno Therapeutics SLNO Stock Holding History

Zurich Cantonal Bank’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,829	Closed	-$363K	–	2598
2026 Q1	$363K	Sell	10,829 -10,246	-49%	-$402K	﹤0.01%	1999
2025 Q4	$976K	Buy	21,075 +13,833	+191%	+$758K	﹤0.01%	1362
2025 Q3	$490K	Buy	7,242 +660	+10%	+$48.9K	﹤0.01%	1752
2025 Q2	$551K	Buy	6,582 +3,507	+114%	+$262K	﹤0.01%	1598
2025 Q1	$220K	Hold	3,075	–	–	﹤0.01%	2055
2024 Q4	$138K	Hold	3,075	–	–	﹤0.01%	2310
2024 Q3	$155K	Buy	+3,075	New	+$147K	﹤0.01%	2241

Zurich Cantonal Bank's SLNO Position: Q2 2026 in Review

Zurich Cantonal Bank sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 10,829 shares — an estimated $363K sold.

Zurich Cantonal Bank first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $976K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Zurich Cantonal Bank reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Zurich Cantonal Bank sold 10,829 Soleno Therapeutics shares in Q2 2026, an estimated $363K.
Zurich Cantonal Bank first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
Zurich Cantonal Bank's Soleno Therapeutics position peaked at $976K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.